In this episode of #SiliconValley2.0, hosted by Sabrina Halper, we bring you a conversation with Vise co-founders Samir Vasavada and Runik Mehrotra. Backed by some of Silicon Valley’s top venture capitalists, they have set out to re-imagine investment management through artificial intelligence and machine learning. With this AI-driven approach, Vise is able to customize the portfolio to the clients’ individual needs and allows advisors to educate their clients on the reasoning behind their investments. The co-founders discuss their personal experience in founding Vise, their understanding of Silicon Valley, how the pandemic has affected their business, and their insights into where the future of investment management is headed. Silicon Valley 2.0 is a fortnightly series that showcases next gen entrepreneurs and businesses that have the potential to scale new heights.
Credit: HT Digital Content Duration: 22:59Published
The U.S. House of Representatives antitrust subcommittee's findings on abuse of market power by four large tech companies took Amazon, Apple, Facebook and Alphabet's Google to task in a scathing take-down for what the committee saw as a gross abuse of power aimed at squelching competition. Conway G. Gittens reports.
The U.S. Food and Drug Administration on Thursday approved Gilead Sciences's antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for..